Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 72

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 72
---
, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including: 

•the clinical indications for which our product candidates are approved; 

•physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; 

•the potential and perceived advantages of our product candidates over alternative treatments; 

•our ability to demonstrate the advantages of our product candidates over other cancer medicines; 

•the prevalence and severity of any side effects; 

•the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines; 

•product labeling or product insert requirements of the FDA or other regulatory authorities; 

 41

•limitations or warnings contained in the labeling approved by the FDA; 

•the timing of market introduction of our product candidates as well as competitive products; 

•the cost of treatment in relation to alternative treatments; 

•the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; 

•the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; 

•relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and 

•the effectiveness of our sales and marketing efforts.

If our product candidates receive regulatory approval but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. 

In addition, although our product candidates differ in certain ways from other precision medicine approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates and a decrease in demand for any such product candidates. 

Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. 

The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would adversely affect our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to